November 2012 - Page 15 of 15

ThursdayNov 01, 2012 12:50 pm

Lifeline Cell Technology Plays Important Role for International Stem Cell Corp. (ISCO)

Lifeline Cell Technology, a wholly owned subsidiary of International Stem Cell Corp., specializes in the research and production of purified human cells and optimized reagents for cell culture. Lifeline helped introduce Normal Human Cell Systems for research over 25 years ago, and developed many of the quality standards that academic, government, and pharmaceutical laboratories use today in the study of human diseases. With laboratory and manufacturing operations in California and Maryland, Lifeline offers researchers a comprehensive range of human cell systems and associated products: • Advanced Skin Test Products • Bladder Cell Systems • Corneal Epithelial Cell Systems • Cryopreservation…

ThursdayNov 01, 2012 11:46 am

Cleantech Solutions International, Inc. (CLNT) Set to Deliver on Two New Purchase Orders for Airflow-Dyeing Machines and Forging Components

Cleantech Solutions, a leading manufacturer of metal components and assemblies, primarily used in the wind power, solar, and other clean technology industries, announced yesterday that it has received purchase orders for airflow-dyeing machines and related components from two additional domestic customers. Cleantech is set to deliver a total of 63 sets of airflow-dyeing machines and related components, as required by the first purchase order, for a total purchase price of approximately $1.7 million (RMB 10.4 million). In accordance with the purchase order, Cleantech has received an advance payment of $0.5 million, or 30% of the total purchase price. Upon installation,…

ThursdayNov 01, 2012 11:45 am

Astex Pharmaceuticals, Inc. (ASTX) Forms Drug Discovery Alliance with CRT and Newcastle

Astex Pharmaceuticals announced yesterday it has signed a five-year strategic drug discovery alliance with Cancer Research Technology Limited (CRT) and Newcastle University. As partners, the three entities will discover and develop new cancer drugs in collaboration with researchers at the Cancer Research UK Drug Discovery Program at the Northern Institute for Cancer Research (NICR, Newcastle University). Astex will provide Newcastle University with GBP1 million annual funding during the five-year alliance, supporting research across biology, chemistry, pharmacology, and imaging at the NICR in order to identify and develop new cancer drugs and associated biomarkers, to develop tests and to determine which…

ThursdayNov 01, 2012 11:44 am

HII Technologies, Inc. (HIIT) Launches Onsite Power Division for E&P Space with Heavy Capital Backup

HII Technologies, the power and water management innovation-focused, Houston-based oilfield services firm with a solid operational footprint in both Texas and Oklahoma, reported launching their new E&P operator-aligned, onsite portable power division today, South Texas Power (STP), in conjunction with issuance of a non-binding letter of intent that will bolster the launch via capital obtained through a strategic alliance with Power Reserve Corp. This is a natural symbiosis of parallel architectures, with Power Reserve heavily deployed in the oilfield equipment space and STP geared towards hooking customers up with the latest and best in mission critical power hardware. STP is…

ThursdayNov 01, 2012 11:43 am

Cardium Therapeutics, Inc. (CXM) Sees Opportunity Outside The U.S.

When the FDA recently announced that it is considering a faster approval process for developers of drugs for serious diseases, it was important news for companies like Cardium Therapeutics, a San Diego-based health sciences and regenerative medicine developer. Development of a significant new drug is expensive and time consuming even without the regulatory requirements, and pressure has been mounting on the FDA to make the process more efficient. The goal of the new process is to allow quicker clinical trials, while also letting physicians administer the drugs to critical need patients where the benefits would outweigh the risks. But pharmaceutical…

ThursdayNov 01, 2012 11:41 am

Keryx Biopharmaceuticals, Inc. (KERX) Begins Phase II Study of Zerenex for Treatment of Patients with Kidney Disease

Keryx Biopharmaceuticals is focused on medically important pharmaceutical products for the treatment of renal disease. The company is currently developing Zerenex (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind phosphate and form non-absorbable complexes. The company today announced the initiation of a Phase 2 study of Zerenex in managing serum phosphorus and iron deficiency in anemic patients with Stage 3 to 5 non-dialysis dependent chronic kidney disease (NDD-CKD). In the U.S. alone, over 1.5 million people suffering from Stages 3-5 NDD-CKD have iron deficiency anemia. However, there are currently no oral iron supplements with an…

ThursdayNov 01, 2012 11:38 am

Issuer Direct Corp. (ISDR) Opens Q3 Books to Show YoY Improvements

Issuer Direct, a provider of disclosure management solutions and cloud-based compliance technologies, today reported its financial results for the third quarter of 2012. The company reported GAAP earnings of $213,591, or $0.11 per share, marking a 200 percent improvement over net income of $71,081, or $0.04 per share, reported in the comparable quarter of 2011. Issuer Direct reported non-GAAP earnings of $300,429, or $0.15 per share, compared to non-GAAP net income of $156,325, or $0.09 per share, for the comparable quarter of 2011. Revenues for the quarter increased by 36 percent to $1.25 million as compared to revenues of $891,576…

Site Search

Company Search

Month: November 2012